Proteotype Diagnostics Patents

Patent portfolio assigned to Proteotype Diagnostics (verified via public assignee records). Cambridge UK multi-cancer early detection (Enlighten test, Protein Cross Sections). Competitors are other multi-cancer early-detection/liquid-biopsy players named in coverage of Proteotype; these are sector competitors, not asserted by the company directly. has_patents=true: company states tech is patent pending in 19 jurisdictions and USPTO US11747205 ('Noninvasive, multispectral-fluorescence characterization of biological tissues with machine/deep learning') matches its technology; exact granted patent count under the company name not confirmed. No named paying customers found (pre-revenue).